Ignite Creation Date:
2024-05-06 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04736589
Status:
NOT_YET_RECRUITING
Last Update Posted:
2021-02-03
First Post:
2021-01-31
Brief Title:
Inetetamab Plus Rapamycin and Chemotherapy for HER2 Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Sponsor:
Peking Union Medical College
Organization:
Peking Union Medical College
Organization Data
Organization:
Peking Union Medical College
Class:
OTHER
Study ID:
IR-11
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Peking Union Medical College
Lead Sponsor Class:
OTHER
Responsible Party:
Fei Ma
Responsible Party Title:
Associate director of the department of Medical Oncology in Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical College
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Peking Union Medical College
Old Name:
None
Old Organization:
None